首頁 > 市場調查報告書 > 製藥

神經疾病

全球重症肌無力治療市場研究報告 - 行業分析、規模、佔有率、成長、趨勢及2023年至2030年預測

市場調查報告書

商品編碼

1306958

全球重症肌無力治療市場研究報告 - 行業分析、規模、佔有率、成長、趨勢及2023年至2030年預測

Global Myasthenia Gravis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年06月01日 | 出版商:

Value Market Research | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

據預測，到2030年，全球重症肌無力治療市場需求將從2022年的28.2億美元達到53.9億美元，2023-2030年的年複合成長率為8.43%。

重症重症肌無力（MG）是一種由自身免疫因素引起的神經肌肉疾病，會導致肌肉無力和疲勞。雖然目前尚無法治愈重症肌無力症，但有多種治療方案可用於控制症狀和改善患者的生活品質。

市場動態：

重症重症肌無力發病率的上升以及人們對該病認知的提高和診斷能力的增強推動了治療市場的發展。醫學研究的進步促進了新的和改進的治療策略的開發。基於疾病嚴重程度和患者特徵的個性化醫療方法最佳化治療效果，並增加了對特定療法的需求。醫療保健專業人員之間的合作加強患者護理和治療策略。患者教育和宣傳工作的加強提高了人們的認知，推動了對有效治療的需求。診斷和監測設備方面的技術進步有助於準確診斷和更佳管理疾病。完善的醫療基礎設施和支持性的保險給付政策對重症重症肌無力治療市場的成長非常重要。這些因素共同促進了重症重症肌無力患者治療方案和治療效果的進步。

研究涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰了解行業結構，評估全球競爭吸引力。此外，這些工具還對全球重症肌無力治療市場的各個細分市場進行了全面評估。重症重症肌無力治療行業的成長和趨勢為本研究提供了整體方法。

區域分析：

本部分涵蓋了區域前景，突出了北美、歐洲、亞太、拉丁美洲、中東和非洲地區重症肌無力治療市場的當前和未來需求。此外，本報告還重點關注了所有主要地區各個應用領域的需求、估計和預測。

本研究還涵蓋了市場主要參與者的綜合概況以及全球競爭格局的深入分析。重症肌無力治療市場的主要參與者包括Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Bausch Health Companies Inc., Shire plc。這部分包括競爭格局的整體視圖，其中包括各種戰略發展，如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品上市和其他發展。

如果您有任何客製化要求，請聯繫我們。我們的研究團隊可以根據您的需求提供客製化服務。

地區展望
地區介紹
北美銷售分析
- 概述、歷史和預測資料銷售分析
- 北美各細分市場銷售分析
- 北美各國銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測資料銷售分析
- 歐洲各細分市場銷售分析
- 歐洲各國銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測資料銷售分析
- 亞太地區細分市場銷售分析
- 亞太地區各國銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 亞太其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測資料銷售分析
- 拉丁美洲各細分市場銷售分析
- 拉丁美洲各國銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測資料銷售分析
- 中東及非洲各細分市場銷售分析
- 中東及非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第8章: 重症重症肌無力企業競爭格局分析

重症重症肌無力治療市場競爭格局
夥伴關係/合作/協議
合併與收購
新產品上市
其他發展

第9章: 公司概況

頂級公司市場佔有率分析
市場集中度
Alexion Pharmaceutical Inc.
- 公司概況
- 公司收入
- 產品
- 近期發展
Grifols SA
- 公司概況
- 公司收入
- 產品
- 近期發展
Avadel Pharmaceuticals plc.
- 公司概況
- 公司收入
- 產品
- 近期發展
Novartis AG
- 公司概況
- 公司收入
- 產品
- 近期發展
Pfizer Inc.
- 公司概況
- 公司收入
- 產品
- 近期發展
AbbVie Inc.
- 公司概況
- 公司收入
- 產品
- 近期發展
F. Hoffmann-La Roche Ltd.
- 公司概況
- 公司收入
- 產品
- 近期發展
GlaxoSmithKline PLC
- 公司概況
- 公司收入
- 產品
- 近期發展
Bausch Health Companies Inc.
- 公司概況
- 公司收入
- 產品
- 近期發展
Shire plc.
- 公司概況
- 公司收入
- 產品
- 近期發展

注-在公司概況中，財務細節和近期發展視情況而定，如果是私營公司則可能不包括在內。

簡介目錄圖表

Product Code: VMR112111360

The global demand for Myasthenia Gravis Treatment Market is presumed to reach the market size of nearly USD 5.39 BN by 2030 from USD 2.82 BN in 2022 with a CAGR of 8.43% under the study period 2023 - 2030.

Myasthenia gravis (MG), a neuromuscular disorder resulting from an autoimmune factor, leads to muscle weakness and fatigue. While a cure for MG is currently unknown, various treatment options exist to manage symptoms and improvise the quality of life for individuals affected by the condition.

MARKET DYNAMICS:

The rising prevalence of Myasthenia gravis, along with improved awareness and diagnostic capabilities, is driving the treatment market. Advancements in medical research are leading to the development of new and improved treatment strategies. Personalized medicine approaches based on disease severity and patient characteristics are optimizing outcomes and increasing the demand for specific therapies. Collaboration among healthcare professionals is enhancing patient care and treatment strategies. Increased patient education and advocacy efforts are creating awareness and driving the demand for effective treatments. Technological advancements in diagnostics and monitoring devices are enabling accurate diagnosis and better management of the disease. A well-developed healthcare infrastructure and supportive reimbursement policies are essential for the growth of the Myasthenia gravis treatment market. These factors collectively contribute to the advancement of treatment options and outcomes for individuals with Myasthenia gravis.

The research covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of myasthenia gravis treatment. The growth and trends of myasthenia gravis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the myasthenia gravis treatment market provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

Medication
Surgery
Others

By End-Use

Hospitals
Clinics
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Myasthenia Gravis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the myasthenia gravis treatment market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Bausch Health Companies Inc., Shire plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized as per your need.

1 . PREFACE

1.1. Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . MYASTHENIA GRAVIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porters Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment
- 3.7.2 Market Attractiveness Analysis By End-Use
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET ANALYSIS BY TREATMENT

5.1 Overview by Treatment
5.2 Historical and Forecast Data
5.3 Analysis by Treatment
5.4 Medication Historic and Forecast Sales by Regions
5.5 Surgery Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET ANALYSIS BY END-USE

6.1 Overview by End-Use
6.2 Historical and Forecast Data
6.3 Analysis by End-Use
6.4 Hospitals Historic and Forecast Sales by Regions
6.5 Clinics Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE MYASTHENIA GRAVIS TREATMENT COMPANIES

8.1. Myasthenia Gravis Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF MYASTHENIA GRAVIS TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Alexion Pharmaceutical Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Grifols SA
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Avadel Pharmaceuticals plc.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Novartis AG
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Pfizer Inc.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. AbbVie Inc.
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. F. Hoffmann-La Roche Ltd.
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. GlaxoSmithKline PLC
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Bausch Health Companies Inc.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Shire plc.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments